A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

NCT06439771 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Breast Cancer

Interventions

DRUG: YL202 should be intravenously infused

Sponsor

MediLink Therapeutics (Suzhou) Co., Ltd.